Sandra Horning, MD
Adding atezolizumab (Tecentriq) to platinum-based chemotherapy significantly improved progression-free survival (PFS) in patients with previously untreated locally advanced or metastatic urothelial carcinoma (mUC), according to results from the phase III IMvigor130 study reported by Genentech, the manufacturer of the PD-L1 inhibitor.1
Based on a separate cohort from the IMvigor210 trial, atezolizumab also received an approval as a treatment for patients with locally advanced or mUC whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.
The IMvigor 210 cohort on which this approval was based included an all-comer population of 316 patients with inoperable locally advanced or mUC who progressed after receiving platinum-based chemotherapy.3 Data from 310 patients were evaluable. The patients had been heavily pretreated, with 40% of patients undergoing 2 or more prior systemic regimens in the metastatic setting and 74% of patients receiving previous cisplatin-based chemotherapy.
... to read the full story